+关注
hi小鳄鱼
暂无个人介绍
IP属地：0
6
关注
1
粉丝
0
主题
0
勋章
主贴
热门
hi小鳄鱼
2021-08-23
在咱们这大环境下，港股基本得凉一段时间了
暗盘：先瑞达医疗-B跌超26%，此前获逾654倍认购
hi小鳄鱼
2021-07-27
厉害，可惜我年龄有点大了，不然还真想为国接盘😒
抱歉，原内容已删除
hi小鳄鱼
2021-05-12
$泡泡玛特(09992)$
是不是彻底凉凉了
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3575603759941328","uuid":"3575603759941328","gmtCreate":1612509736021,"gmtModify":1620800464138,"name":"hi小鳄鱼","pinyin":"hixeyhixiaoeyu","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/7914b3faf2dd01a2e8bdd8beb7887e28","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":6,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.00%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.18%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"0","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":835876168,"gmtCreate":1629707456954,"gmtModify":1629707456954,"author":{"id":"3575603759941328","authorId":"3575603759941328","name":"hi小鳄鱼","avatar":"https://static.tigerbbs.com/7914b3faf2dd01a2e8bdd8beb7887e28","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575603759941328","authorIdStr":"3575603759941328"},"themes":[],"htmlText":"在咱们这大环境下，港股基本得凉一段时间了","listText":"在咱们这大环境下，港股基本得凉一段时间了","text":"在咱们这大环境下，港股基本得凉一段时间了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/835876168","repostId":"1183822547","repostType":4,"repost":{"id":"1183822547","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1629706678,"share":"https://www.laohu8.com/m/news/1183822547?lang=&edition=full","pubTime":"2021-08-23 16:17","market":"hk","language":"zh","title":"暗盘：先瑞达医疗-B跌超26%，此前获逾654倍认购","url":"https://stock-news.laohu8.com/highlight/detail?id=1183822547","media":"老虎资讯综合","summary":"8月23日消息，先瑞达医疗-B暗盘报17.5港元，较发行价跌26.47%。公司每股定价23.8港元，每手1000股，将于8月24日（周二）港股上市。\n\n公开发售阶段先瑞达医疗获约654.51倍认购，","content":"<p>8月23日消息，<a href=\"https://laohu8.com/S/06669\">先瑞达医疗-B</a>暗盘报17.5港元，较发行价跌26.47%。公司每股定价23.8港元，每手1000股，将于8月24日（周二）港股上市。</p>\n<p><img src=\"https://static.tigerbbs.com/518a125cb15d68545d7248ded8786752\" tg-width=\"1080\" tg-height=\"2250\" referrerpolicy=\"no-referrer\"></p>\n<p>公开发售阶段先瑞达医疗获约654.51倍认购，分配至公开发售的发售股份最终数目为3431.8万股，占发售股份总数的约50%（任何超额配股权获行使前）。合共接获310661份有效申请，一手中签率3%，认购200手稳中一手。</p>\n<p>此外，国际发售已获超额认购，发售股份最终数目为3431.5万股，相当于发售股份总数的约50%（任何超额配股权获行使前）。老虎资讯整理相关数据如下表：</p>\n<p><img src=\"https://static.tigerbbs.com/11a4aa099d57c3457eaf96f7ae36b32f\" tg-width=\"697\" tg-height=\"584\" referrerpolicy=\"no-referrer\"></p>\n<p>甲组每手1000股，一手中签率3%，认购200手稳中一手。</p>\n<p>乙组门槛为25万股（1250手），获配2000股（2手）。<img src=\"https://static.tigerbbs.com/740152f2007693f65f5e418d5cdb7062\" tg-width=\"735\" tg-height=\"782\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/92f44c14a652c527f2da790c4c93f0a4\" tg-width=\"771\" tg-height=\"778\" referrerpolicy=\"no-referrer\"></p>\n<p></p>\n<p></p>\n<p>所得款项净额约15.29亿港元将用作以下用途：32%将被分配给核心产品；23%将分配给现有产品管线中余下的24款产品；7%用于扩大生产能力及强化制造能力；24%用于通过内部研发、合作、合并及收购、授权引进或股权投资等方式扩大公司产品组合；8%拨作营运资金及一般企业用途；6%拨作偿还贷款。</p>\n<p>据悉，先瑞达医疗是一家领先的中国创新医疗器械企业，专注于提供血管疾病的「介入无植入」治疗方案。截至最后实际可行日期，公司已有四款产品实现商业化，产品管线涵盖24款处于不同开发阶段的在研产品。</p>\n<p>财务数据方面，公司于PTA球囊及DCB产品推出后开始产生收益。于2019年、2020年及2021年前三个月，公司录得收益人民币1.25亿元、1.94亿元及5332万元，同期录得净利润人民币2310.5万元、-4429.2万元及-4001.6万元。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>暗盘：先瑞达医疗-B跌超26%，此前获逾654倍认购</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n暗盘：先瑞达医疗-B跌超26%，此前获逾654倍认购\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-08-23 16:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>8月23日消息，<a href=\"https://laohu8.com/S/06669\">先瑞达医疗-B</a>暗盘报17.5港元，较发行价跌26.47%。公司每股定价23.8港元，每手1000股，将于8月24日（周二）港股上市。</p>\n<p><img src=\"https://static.tigerbbs.com/518a125cb15d68545d7248ded8786752\" tg-width=\"1080\" tg-height=\"2250\" referrerpolicy=\"no-referrer\"></p>\n<p>公开发售阶段先瑞达医疗获约654.51倍认购，分配至公开发售的发售股份最终数目为3431.8万股，占发售股份总数的约50%（任何超额配股权获行使前）。合共接获310661份有效申请，一手中签率3%，认购200手稳中一手。</p>\n<p>此外，国际发售已获超额认购，发售股份最终数目为3431.5万股，相当于发售股份总数的约50%（任何超额配股权获行使前）。老虎资讯整理相关数据如下表：</p>\n<p><img src=\"https://static.tigerbbs.com/11a4aa099d57c3457eaf96f7ae36b32f\" tg-width=\"697\" tg-height=\"584\" referrerpolicy=\"no-referrer\"></p>\n<p>甲组每手1000股，一手中签率3%，认购200手稳中一手。</p>\n<p>乙组门槛为25万股（1250手），获配2000股（2手）。<img src=\"https://static.tigerbbs.com/740152f2007693f65f5e418d5cdb7062\" tg-width=\"735\" tg-height=\"782\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/92f44c14a652c527f2da790c4c93f0a4\" tg-width=\"771\" tg-height=\"778\" referrerpolicy=\"no-referrer\"></p>\n<p></p>\n<p></p>\n<p>所得款项净额约15.29亿港元将用作以下用途：32%将被分配给核心产品；23%将分配给现有产品管线中余下的24款产品；7%用于扩大生产能力及强化制造能力；24%用于通过内部研发、合作、合并及收购、授权引进或股权投资等方式扩大公司产品组合；8%拨作营运资金及一般企业用途；6%拨作偿还贷款。</p>\n<p>据悉，先瑞达医疗是一家领先的中国创新医疗器械企业，专注于提供血管疾病的「介入无植入」治疗方案。截至最后实际可行日期，公司已有四款产品实现商业化，产品管线涵盖24款处于不同开发阶段的在研产品。</p>\n<p>财务数据方面，公司于PTA球囊及DCB产品推出后开始产生收益。于2019年、2020年及2021年前三个月，公司录得收益人民币1.25亿元、1.94亿元及5332万元，同期录得净利润人民币2310.5万元、-4429.2万元及-4001.6万元。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","relate_stocks":{"06669":"先瑞达医疗-B"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183822547","content_text":"8月23日消息，先瑞达医疗-B暗盘报17.5港元，较发行价跌26.47%。公司每股定价23.8港元，每手1000股，将于8月24日（周二）港股上市。\n\n公开发售阶段先瑞达医疗获约654.51倍认购，分配至公开发售的发售股份最终数目为3431.8万股，占发售股份总数的约50%（任何超额配股权获行使前）。合共接获310661份有效申请，一手中签率3%，认购200手稳中一手。\n此外，国际发售已获超额认购，发售股份最终数目为3431.5万股，相当于发售股份总数的约50%（任何超额配股权获行使前）。老虎资讯整理相关数据如下表：\n\n甲组每手1000股，一手中签率3%，认购200手稳中一手。\n乙组门槛为25万股（1250手），获配2000股（2手）。\n\n\n所得款项净额约15.29亿港元将用作以下用途：32%将被分配给核心产品；23%将分配给现有产品管线中余下的24款产品；7%用于扩大生产能力及强化制造能力；24%用于通过内部研发、合作、合并及收购、授权引进或股权投资等方式扩大公司产品组合；8%拨作营运资金及一般企业用途；6%拨作偿还贷款。\n据悉，先瑞达医疗是一家领先的中国创新医疗器械企业，专注于提供血管疾病的「介入无植入」治疗方案。截至最后实际可行日期，公司已有四款产品实现商业化，产品管线涵盖24款处于不同开发阶段的在研产品。\n财务数据方面，公司于PTA球囊及DCB产品推出后开始产生收益。于2019年、2020年及2021年前三个月，公司录得收益人民币1.25亿元、1.94亿元及5332万元，同期录得净利润人民币2310.5万元、-4429.2万元及-4001.6万元。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1583,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":809404994,"gmtCreate":1627384454518,"gmtModify":1627384454518,"author":{"id":"3575603759941328","authorId":"3575603759941328","name":"hi小鳄鱼","avatar":"https://static.tigerbbs.com/7914b3faf2dd01a2e8bdd8beb7887e28","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575603759941328","authorIdStr":"3575603759941328"},"themes":[],"htmlText":"厉害，可惜我年龄有点大了，不然还真想为国接盘😒","listText":"厉害，可惜我年龄有点大了，不然还真想为国接盘😒","text":"厉害，可惜我年龄有点大了，不然还真想为国接盘😒","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/809404994","repostId":"1122277876","repostType":4,"isVote":1,"tweetType":1,"viewCount":1145,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":193596923,"gmtCreate":1620796683962,"gmtModify":1620800159835,"author":{"id":"3575603759941328","authorId":"3575603759941328","name":"hi小鳄鱼","avatar":"https://static.tigerbbs.com/7914b3faf2dd01a2e8bdd8beb7887e28","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575603759941328","authorIdStr":"3575603759941328"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/09992\">$泡泡玛特(09992)$</a>是不是彻底凉凉了","listText":"<a href=\"https://laohu8.com/S/09992\">$泡泡玛特(09992)$</a>是不是彻底凉凉了","text":"$泡泡玛特(09992)$是不是彻底凉凉了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/193596923","isVote":1,"tweetType":1,"viewCount":1946,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3479365438882343","authorId":"3479365438882343","name":"5ae3cb83","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"idStr":"3479365438882343","authorIdStr":"3479365438882343"},"content":"我这套的死死的","text":"我这套的死死的","html":"我这套的死死的"}],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":809404994,"gmtCreate":1627384454518,"gmtModify":1627384454518,"author":{"id":"3575603759941328","authorId":"3575603759941328","name":"hi小鳄鱼","avatar":"https://static.tigerbbs.com/7914b3faf2dd01a2e8bdd8beb7887e28","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575603759941328","authorIdStr":"3575603759941328"},"themes":[],"htmlText":"厉害，可惜我年龄有点大了，不然还真想为国接盘😒","listText":"厉害，可惜我年龄有点大了，不然还真想为国接盘😒","text":"厉害，可惜我年龄有点大了，不然还真想为国接盘😒","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/809404994","repostId":"1122277876","repostType":4,"isVote":1,"tweetType":1,"viewCount":1145,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":193596923,"gmtCreate":1620796683962,"gmtModify":1620800159835,"author":{"id":"3575603759941328","authorId":"3575603759941328","name":"hi小鳄鱼","avatar":"https://static.tigerbbs.com/7914b3faf2dd01a2e8bdd8beb7887e28","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575603759941328","authorIdStr":"3575603759941328"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/09992\">$泡泡玛特(09992)$</a>是不是彻底凉凉了","listText":"<a href=\"https://laohu8.com/S/09992\">$泡泡玛特(09992)$</a>是不是彻底凉凉了","text":"$泡泡玛特(09992)$是不是彻底凉凉了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/193596923","isVote":1,"tweetType":1,"viewCount":1946,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3479365438882343","authorId":"3479365438882343","name":"5ae3cb83","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"idStr":"3479365438882343","authorIdStr":"3479365438882343"},"content":"我这套的死死的","text":"我这套的死死的","html":"我这套的死死的"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":835876168,"gmtCreate":1629707456954,"gmtModify":1629707456954,"author":{"id":"3575603759941328","authorId":"3575603759941328","name":"hi小鳄鱼","avatar":"https://static.tigerbbs.com/7914b3faf2dd01a2e8bdd8beb7887e28","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575603759941328","authorIdStr":"3575603759941328"},"themes":[],"htmlText":"在咱们这大环境下，港股基本得凉一段时间了","listText":"在咱们这大环境下，港股基本得凉一段时间了","text":"在咱们这大环境下，港股基本得凉一段时间了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/835876168","repostId":"1183822547","repostType":4,"repost":{"id":"1183822547","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1629706678,"share":"https://www.laohu8.com/m/news/1183822547?lang=&edition=full","pubTime":"2021-08-23 16:17","market":"hk","language":"zh","title":"暗盘：先瑞达医疗-B跌超26%，此前获逾654倍认购","url":"https://stock-news.laohu8.com/highlight/detail?id=1183822547","media":"老虎资讯综合","summary":"8月23日消息，先瑞达医疗-B暗盘报17.5港元，较发行价跌26.47%。公司每股定价23.8港元，每手1000股，将于8月24日（周二）港股上市。\n\n公开发售阶段先瑞达医疗获约654.51倍认购，","content":"<p>8月23日消息，<a href=\"https://laohu8.com/S/06669\">先瑞达医疗-B</a>暗盘报17.5港元，较发行价跌26.47%。公司每股定价23.8港元，每手1000股，将于8月24日（周二）港股上市。</p>\n<p><img src=\"https://static.tigerbbs.com/518a125cb15d68545d7248ded8786752\" tg-width=\"1080\" tg-height=\"2250\" referrerpolicy=\"no-referrer\"></p>\n<p>公开发售阶段先瑞达医疗获约654.51倍认购，分配至公开发售的发售股份最终数目为3431.8万股，占发售股份总数的约50%（任何超额配股权获行使前）。合共接获310661份有效申请，一手中签率3%，认购200手稳中一手。</p>\n<p>此外，国际发售已获超额认购，发售股份最终数目为3431.5万股，相当于发售股份总数的约50%（任何超额配股权获行使前）。老虎资讯整理相关数据如下表：</p>\n<p><img src=\"https://static.tigerbbs.com/11a4aa099d57c3457eaf96f7ae36b32f\" tg-width=\"697\" tg-height=\"584\" referrerpolicy=\"no-referrer\"></p>\n<p>甲组每手1000股，一手中签率3%，认购200手稳中一手。</p>\n<p>乙组门槛为25万股（1250手），获配2000股（2手）。<img src=\"https://static.tigerbbs.com/740152f2007693f65f5e418d5cdb7062\" tg-width=\"735\" tg-height=\"782\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/92f44c14a652c527f2da790c4c93f0a4\" tg-width=\"771\" tg-height=\"778\" referrerpolicy=\"no-referrer\"></p>\n<p></p>\n<p></p>\n<p>所得款项净额约15.29亿港元将用作以下用途：32%将被分配给核心产品；23%将分配给现有产品管线中余下的24款产品；7%用于扩大生产能力及强化制造能力；24%用于通过内部研发、合作、合并及收购、授权引进或股权投资等方式扩大公司产品组合；8%拨作营运资金及一般企业用途；6%拨作偿还贷款。</p>\n<p>据悉，先瑞达医疗是一家领先的中国创新医疗器械企业，专注于提供血管疾病的「介入无植入」治疗方案。截至最后实际可行日期，公司已有四款产品实现商业化，产品管线涵盖24款处于不同开发阶段的在研产品。</p>\n<p>财务数据方面，公司于PTA球囊及DCB产品推出后开始产生收益。于2019年、2020年及2021年前三个月，公司录得收益人民币1.25亿元、1.94亿元及5332万元，同期录得净利润人民币2310.5万元、-4429.2万元及-4001.6万元。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>暗盘：先瑞达医疗-B跌超26%，此前获逾654倍认购</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n暗盘：先瑞达医疗-B跌超26%，此前获逾654倍认购\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-08-23 16:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>8月23日消息，<a href=\"https://laohu8.com/S/06669\">先瑞达医疗-B</a>暗盘报17.5港元，较发行价跌26.47%。公司每股定价23.8港元，每手1000股，将于8月24日（周二）港股上市。</p>\n<p><img src=\"https://static.tigerbbs.com/518a125cb15d68545d7248ded8786752\" tg-width=\"1080\" tg-height=\"2250\" referrerpolicy=\"no-referrer\"></p>\n<p>公开发售阶段先瑞达医疗获约654.51倍认购，分配至公开发售的发售股份最终数目为3431.8万股，占发售股份总数的约50%（任何超额配股权获行使前）。合共接获310661份有效申请，一手中签率3%，认购200手稳中一手。</p>\n<p>此外，国际发售已获超额认购，发售股份最终数目为3431.5万股，相当于发售股份总数的约50%（任何超额配股权获行使前）。老虎资讯整理相关数据如下表：</p>\n<p><img src=\"https://static.tigerbbs.com/11a4aa099d57c3457eaf96f7ae36b32f\" tg-width=\"697\" tg-height=\"584\" referrerpolicy=\"no-referrer\"></p>\n<p>甲组每手1000股，一手中签率3%，认购200手稳中一手。</p>\n<p>乙组门槛为25万股（1250手），获配2000股（2手）。<img src=\"https://static.tigerbbs.com/740152f2007693f65f5e418d5cdb7062\" tg-width=\"735\" tg-height=\"782\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/92f44c14a652c527f2da790c4c93f0a4\" tg-width=\"771\" tg-height=\"778\" referrerpolicy=\"no-referrer\"></p>\n<p></p>\n<p></p>\n<p>所得款项净额约15.29亿港元将用作以下用途：32%将被分配给核心产品；23%将分配给现有产品管线中余下的24款产品；7%用于扩大生产能力及强化制造能力；24%用于通过内部研发、合作、合并及收购、授权引进或股权投资等方式扩大公司产品组合；8%拨作营运资金及一般企业用途；6%拨作偿还贷款。</p>\n<p>据悉，先瑞达医疗是一家领先的中国创新医疗器械企业，专注于提供血管疾病的「介入无植入」治疗方案。截至最后实际可行日期，公司已有四款产品实现商业化，产品管线涵盖24款处于不同开发阶段的在研产品。</p>\n<p>财务数据方面，公司于PTA球囊及DCB产品推出后开始产生收益。于2019年、2020年及2021年前三个月，公司录得收益人民币1.25亿元、1.94亿元及5332万元，同期录得净利润人民币2310.5万元、-4429.2万元及-4001.6万元。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","relate_stocks":{"06669":"先瑞达医疗-B"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183822547","content_text":"8月23日消息，先瑞达医疗-B暗盘报17.5港元，较发行价跌26.47%。公司每股定价23.8港元，每手1000股，将于8月24日（周二）港股上市。\n\n公开发售阶段先瑞达医疗获约654.51倍认购，分配至公开发售的发售股份最终数目为3431.8万股，占发售股份总数的约50%（任何超额配股权获行使前）。合共接获310661份有效申请，一手中签率3%，认购200手稳中一手。\n此外，国际发售已获超额认购，发售股份最终数目为3431.5万股，相当于发售股份总数的约50%（任何超额配股权获行使前）。老虎资讯整理相关数据如下表：\n\n甲组每手1000股，一手中签率3%，认购200手稳中一手。\n乙组门槛为25万股（1250手），获配2000股（2手）。\n\n\n所得款项净额约15.29亿港元将用作以下用途：32%将被分配给核心产品；23%将分配给现有产品管线中余下的24款产品；7%用于扩大生产能力及强化制造能力；24%用于通过内部研发、合作、合并及收购、授权引进或股权投资等方式扩大公司产品组合；8%拨作营运资金及一般企业用途；6%拨作偿还贷款。\n据悉，先瑞达医疗是一家领先的中国创新医疗器械企业，专注于提供血管疾病的「介入无植入」治疗方案。截至最后实际可行日期，公司已有四款产品实现商业化，产品管线涵盖24款处于不同开发阶段的在研产品。\n财务数据方面，公司于PTA球囊及DCB产品推出后开始产生收益。于2019年、2020年及2021年前三个月，公司录得收益人民币1.25亿元、1.94亿元及5332万元，同期录得净利润人民币2310.5万元、-4429.2万元及-4001.6万元。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1583,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
